Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
Marta Peña(Institut Català d'Oncologia), Alberto Mussetti(Duran i Reynals Hospital), Ana Jiménez Ubieto(Hospital Universitario 12 De Octubre), Jacopo Mariotti(Istituti di Ricovero e Cura a Carattere Scientifico), Marjolein van der Poel(Maastricht University), Giulia Losi(University of Pavia), Yasmina Serroukh(Erasmus MC), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Mi Kwon(Hospital General Universitario Gregorio Marañón), Leyre Bento De Miguel(Health Research Institute of the Balearic Islands), Stéfania Bramanti(Istituti di Ricovero e Cura a Carattere Scientifico), Philippe Armand(Harvard University), Lucía López‐Corral(Instituto de Investigación Biomédica de Salamanca), Aitana Balaguer‐Roselló(Hospital Universitari i Politècnic La Fe), Blanca Rius‐Sansalvador(Institut d'Investigació Biomédica de Bellvitge), Carmen Albo López(Complexo Hospitalario Universitario A Coruña), Nicole Fabbri(Institut Català d'Oncologia), Carlos Panizo, Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Andrés Sánchez‐Salinas(Hospital Universitario Virgen de la Arrixaca), Ángel Serna(Vall d'Hebron Institut de Recerca), David Qualls(Memorial Sloan Kettering Cancer Center), Marco Aurélio Salvino(Institut d'Investigació Biomédica de Bellvitge), Jennifer L. Crombie(Dana-Farber Cancer Institute), María Calbacho(Hospital Universitario 12 De Octubre), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Ya‐Ting Hsu(National Cheng Kung University Hospital), Manuel Jurado, María Del Mar Perera Álvarez(Hospital Universitario de Gran Canaria Doctor Negrín), Montserrat Rovira(Humanitas University), Inmaculada Heras(Hospital General Universitario Morales Meseguer), Sebastián Garzón(Hospital Jerez Puerta del Sur), Felipe Peña(Institut d'Investigació Biomédica de Bellvitge), Rosario Varela(Complexo Hospitalario Universitario A Coruña), Christopher McKinnely(Fiona Stanley Hospital), David Valcárcel(Vall d'Hebron Hospital Universitari)
Cited by 2
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484